Free Trial

Mirum Pharmaceuticals (MIRM) Earnings Date, Estimates & Call Transcripts

Mirum Pharmaceuticals logo
$47.06 +0.04 (+0.09%)
Closing price 03/25/2025 04:00 PM Eastern
Extended Trading
$48.28 +1.22 (+2.60%)
As of 03/25/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mirum Pharmaceuticals Latest Earnings Summary

Upcoming Q1
Earnings Date
May. 6After Market ClosesEstimated
Actual EPS
(Feb. 26)
-$0.49 Missed By -$0.22
Consensus EPS
(Feb. 26)
-$0.27

Mirum Pharmaceuticals announced Q4 2024 earnings on February 26, 2025, reporting an EPS of -$0.49, which missed analysts' consensus estimates of -$0.27 by $0.22. Quarterly revenue was reported to be $99.41 million, above the consensus estimate of $96.64 million. With a trailing EPS of -$1.85, Mirum Pharmaceuticals' earnings are expected to grow next year, from ($1.43) to ($0.70) per share.

MIRM Upcoming Earnings

Mirum Pharmaceuticals' next earnings date is estimated for Tuesday, May 6, 2025, based off prior year's reporting schedules.

Get Mirum Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mirum Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

MIRM Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

MIRM Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.
Remove Ads

Mirum Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20251-$0.09-$0.09-$0.09
Q2 20251$0.12$0.12$0.12
Q3 20252-$0.25$0.35$0.05
Q4 20251$0.61$0.61$0.61
FY 20255$0.39$0.99$0.69
Remove Ads

Mirum Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/6/2025
(Estimated)
-------
2/26/2025Q4 2024-$0.27-$0.49 -$0.22-$0.49$96.64M$99.41M
11/12/2024Q3 2024-$0.45-$0.30+$0.15-$0.30$81.99M$90.38M
8/7/2024Q2 2024-$0.47-$0.52 -$0.05-$0.52$75.03M$77.90M
5/8/2024Q1 2024-$0.40-$0.54 -$0.14-$0.54$69.71M$69.22M
2/28/2024Q4 2023-$0.34-$0.66 -$0.32-$0.66$66.73M$69.55M
11/2/2023Q3 2023-$0.64-$0.57+$0.07-$0.57$34.31M$47.73M
8/3/2023Q2 2023-$0.81-$0.92 -$0.11$0.10$30.00M$37.50M
5/4/2023Q1 2023-$0.96-$0.80+$0.16-$0.80$30.58M$31.60M

Mirum Pharmaceuticals Earnings - Frequently Asked Questions

Mirum Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based off last year's report dates. Learn more on MIRM's earnings history.

Mirum Pharmaceuticals issued an update on its FY 2025 earnings guidance on Wednesday, February, 26th. The company issued revenue guidance of $420.0 million-, compared to the consensus revenue estimate of $425.5 million.

In the previous quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) missed the analysts' consensus estimate of ($0.27) by $0.22 with a reported earnings per share (EPS) of ($0.49). Learn more on analysts' earnings estimate vs. MIRM's actual earnings.

The conference call for Mirum Pharmaceuticals's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Mirum Pharmaceuticals's latest earnings report can be read online.
Read Transcript

Mirum Pharmaceuticals's earnings report can be found in their filing with the SEC.
View SEC filing

Mirum Pharmaceuticals (NASDAQ:MIRM) has a recorded annual revenue of $336.89 million.

Mirum Pharmaceuticals (NASDAQ:MIRM) has a recorded net income of -$163.41 million. MIRM has generated -$1.85 earnings per share over the last four quarters.

Mirum Pharmaceuticals's earnings are expected to grow from ($1.43) per share to ($0.70) per share in the next year.

More Earnings Resources from MarketBeat

Remove Ads


This page (NASDAQ:MIRM) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners